HQL (abrdn Life Sciences Investors) LT-Debt-to-Total-Asset: 0.00 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HQL abrdn Life Sciences Investors HQL
51 GF Score
Price $22.08
GF Value $62.01
Valuation Significantly Undervalued
! 5 Warning Signs
View Full Analysis

What is abrdn Life Sciences Investors LT-Debt-to-Total-Asset?

abrdn Life Sciences Investors HQL -2.60% 51 LT-Debt-to-Total-Asset is 0.00 as of Mar. 2026. GuruFocus rates HQL with a GF Score™ of 51/100 and a GF Value™ of $62.01 (Significantly Undervalued). The stock has 5 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. abrdn Life Sciences Investors's long-term debt to total assests ratio for the quarter that ended in Mar. 2026 was 0.00.

abrdn Life Sciences Investors's long-term debt to total assets ratio stayed the same from Mar. 2025 (0.00) to Mar. 2026 (0.00).

abrdn Life Sciences Investors  (NYSE:HQL) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

abrdn Life Sciences Investors LT-Debt-to-Total-Asset Related Terms

abrdn Life Sciences Investors LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for abrdn Life Sciences Investors's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

abrdn Life Sciences Investors LT-Debt-to-Total-Asset Chart

abrdn Life Sciences Investors Annual Data
Trend Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial Premium Member Only 0.00 0.00 0.00 0.00 0.00

abrdn Life Sciences Investors Semi-Annual Data
Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
HQL
51GF Score
abrdn Life Sciences Investors HQL
LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

abrdn Life Sciences Investors LT-Debt-to-Total-Asset Calculation

abrdn Life Sciences Investors's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Sep. 2025 is calculated as

LT Debt to Total Assets (A: Sep. 2025 )=Long-Term Debt & Capital Lease Obligation (A: Sep. 2025 )/Total Assets (A: Sep. 2025 )
=0/515.382
=0.00

abrdn Life Sciences Investors's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2026 is calculated as

LT Debt to Total Assets (Q: Mar. 2026 )=Long-Term Debt & Capital Lease Obligation (Q: Mar. 2026 )/Total Assets (Q: Mar. 2026 )
=0/563.226
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →
What does a LT-Debt-to-Total-Asset of 0.00 mean?
abrdn Life Sciences Investors (HQL) has a LT-Debt-to-Total-Asset of 0.00 as of Mar. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on abrdn Life Sciences Investors and its competitors.
Is abrdn Life Sciences Investors' LT-Debt-to-Total-Asset too high?
abrdn Life Sciences Investors' current LT-Debt-to-Total-Asset is 0.00. Overall, abrdn Life Sciences Investors has a GF Score™ of 51/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does abrdn Life Sciences Investors' LT-Debt-to-Total-Asset compare to IIM and NOAH?
abrdn Life Sciences Investors' LT-Debt-to-Total-Asset of 0.00 can be compared against companies in the Asset Management industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for an Asset Management company?
A good LT-Debt-to-Total-Asset depends on the Asset Management industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on abrdn Life Sciences Investors and its competitors. abrdn Life Sciences Investors's current LT-Debt-to-Total-Asset is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is abrdn Life Sciences Investors stock overvalued right now?
Based on GuruFocus' analysis, abrdn Life Sciences Investors (HQL) is currently considered Significantly Undervalued. The stock's GF Value™ is $62.01, compared to a current price of $22.08 — trading 64.4% below its estimated fair value. The current LT-Debt-to-Total-Asset is 0.00. abrdn Life Sciences Investors' overall GF Score™ is 51/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For abrdn Life Sciences Investors (HQL), the current LT-Debt-to-Total-Asset is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is abrdn Life Sciences Investors (HQL) Overvalued in 2026?

Based on GuruFocus' analysis, abrdn Life Sciences Investors stock appears to be undervalued. The current stock price of $22.08 is trading 64.4% below its estimated GF Value™ of $62.01. GuruFocus considers abrdn Life Sciences Investors to be Significantly Undervalued.

Key valuation signals for HQL:

  • LT-Debt-to-Total-Asset: 0.00
  • GF Value™: $62.01 vs. price of $22.08 (64.4% below fair value)
  • GF Score™: 51/100 with 5 warning signs

No single metric tells the full story. See the HQL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

abrdn Life Sciences Investors Business Description

Address 1900 Market Street, Suite 200, Philadelphia, PA, USA, 19103
abrdn Life Sciences Investors operates as a non-diversified closed-end management investment company. Its investment objective is to seek long-term capital appreciation by investing mainly in securities of life sciences companies. It invests in securities of public and private companies that are believed by the Fund's Investment Adviser to have the potential for above-average growth.
51GF Score

Get the complete analysis for HQL

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$22.08
Price
$62.01
GF Value